NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study, which assessed Primec for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Takeda has announced data from the phase 3 advance-cidp 3 trial, which assessed the safety and efficacy of Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) in patients with chronic inflammatory dymyelinating polyneuropathy (CIDP).

Sanofi has announced new phase 2 trial data for its cd40l monoclonal antibody, frexalimab, for the treatment of patients with relapsing multiple sclerosis (MS).

GSK and CureVac have announced that they have restructured their existing collaboration into a licence agreement, which is intended to allow both companies to prioritise investment and focus their respective MRNA development programmes.

Evotec has announced that it has reached important scientific progress within the neuroscience collaboration with Bristol Myers Squibb, initiating a research payment of $20m to Evotec.

Syngene has announced the launch of its new protein production platform, which will utilise a cell line and transposon-based technology in-licensed from excellgene alongside syngene’s clone selection and development processes.

Nuclera has announced that it has been awarded two grants from Innovate UK, totalling £1.14m.

Gilead Sciences has announced results from an interim analysis of its pivotal, phase 3 PURPOSE 1 trial, which assessed the twice-yearly treatment with injectable HIV-1 capsid inhibitor, lencapavir, for the investigational use of HIV prevention in cisgender women.

Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with the aim of building AI-powered software to accelerate the drug development process and bring new drugs to market and to patients more efficiently.

GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first founding partner of the innovative and collaborative approach to tackle antimicrobial resistance (AMR).

OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership.

Johnson & Johnson has announced the first data from its phase 3 QUASAR maintenance study, which assessed Tremfya (guselkumab) as a treatment for patients with moderately-to-severely active ulcerative colitis (UC).